Osteoarthritis is under clinical development by Purecell Group and currently in Phase II for Osteoarthritis. According to GlobalData, Phase II drugs for Osteoarthritis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Osteoarthritis LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Purecell Group overview
Purecell Group is a translational research center engaged in offering analytical testing for drug development, manufacturing and other medical products. The company is headquartered in Sydney, New South Wales, Australia.
For a complete picture of Osteoarthritis’s drug-specific PTSR and LoA scores, buy the report here.